Evidence map›Paper›PMID 33945507›Full record

ArticleJCI insight2021

Role of MIF in coordinated expression of hepatic chemokines in patients with alcohol-associated hepatitis.

Kyle L Poulsen, Xiude Fan, Christopher D Kibler, Emily Huang, Xiaoqin Wu, Megan R McMullen, Lin Leng, Richard Bucala, Meritxell Ventura-Cots, Josepmaria Argemi and 2 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Resident CD24Acta biochimica et biophysica Sinica · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.International journal of molecular sciences · 2022
    Review
  10. Review
  11. Article
  12. Pathogenesis of Alcohol-Associated Liver Disease.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Kyle L PoulsenCenter for Liver Disease Research, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Xiude FanCenter for Liver Disease Research, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Christopher D KiblerCenter for Liver Disease Research, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Emily HuangCenter for Liver Disease Research, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Xiaoqin WuCenter for Liver Disease Research, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Megan R McMullenCenter for Liver Disease Research, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Lin LengDepartment of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Richard BucalaDepartment of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Meritxell Ventura-CotsDivision of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh Liver Research Center, Pittsburgh, Pennsylvania, USA.
Josepmaria ArgemiDivision of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh Liver Research Center, Pittsburgh, Pennsylvania, USA.
Ramon BatallerDivision of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh Liver Research Center, Pittsburgh, Pennsylvania, USA.
Laura E NagyCenter for Liver Disease Research, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.
Cleveland Clinic · USUniversity of Pittsburgh Medical Center · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Project Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI LAURA E. NAGY · 2016 to 2026
$19.6M
Mechanisms of Rheumatoid Synovial Fibroblast ActivationR01AR049610 · NIAMS · YALE UNIVERSITY · PI BUCALA, RICHARD J · 2002 to 2018
$5.0M
IRAKM and Mincle in ALDR01AA023722 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI LI, XIAOXIA, NAGY, LAURA E. · 2015 to 2019
$2.2M
MIF in progression and treatment of ALDU01AA020821 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2012 to 2016
$2.1M
Novel therapeutics for alcoholic hepatitis - Cleveland Translational ComponentU01AA021890 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2012 to 2017
$1.6M
Microbial metabolites and Innate Immunity in AH: Biomarkers of injury and repairU01AA026938 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2018 to 2023
$1.4M
HEPATOCYTE-DERIVED MIF: A KEY CONTRIBUTOR TO ALCOHOLIC LIVER DISEASER00AA026648 · NIAAA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI POULSEN, KYLE · 2020 to 2022
$747k
Hepatocyte-derived MIF: a key contributor to Alcoholic Liver DiseaseK99AA026648 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI POULSEN, KYLE · 2018 to 2019
$258k
NCATS NIH HHS UL1 TR001863NIAAA NIH HHS K99 AA026648NIAAA NIH HHS P50 AA024333NIAAA NIH HHS R00 AA026648NIAAA NIH HHS R01 AA023722NIAAA NIH HHS U01 AA020821NIAAA NIH HHS U01 AA021890NIAAA NIH HHS U01 AA026938NIAMS NIH HHS R01 AR049610
6 · The paper itself

Abstract

The chemokine system of ligands and receptors is implicated in the progression of alcohol-associated hepatitis (AH). Finding upstream regulators could lead to novel therapies. This study involved coordinated expression of chemokines in livers of healthy controls (HC) and patients with AH in 2 distinct cohorts of patients with various chronic liver diseases. Studies in cultured hepatocytes and in tissue-specific KO were used for mechanistic insight into a potential upstream regulator of chemokine expression in AH. Selected C-X-C chemokine members of the IL-8 chemokine family and C-C chemokine CCL20 were highly associated with AH compared with HC but not in patients with liver diseases of other etiologies (nonalcoholic fatty liver disease [NAFLD] and hepatitis C virus [HCV]). Our previous studies implicate macrophage migration inhibitory factor (MIF) as a pleiotropic cytokine/chemokine with the potential to coordinately regulate chemokine expression in AH. LPS-stimulated expression of multiple chemokines in cultured hepatocytes was dependent on MIF. Gao-binge ethanol feeding to mice induced a similar coordinated chemokine expression in livers of WT mice; this was prevented in hepatocyte-specific Mif-KO (MifΔHep) mice. This study demonstrates that patients with AH exhibit a specific, coordinately expressed chemokine signature and that hepatocyte-derived MIF might drive this inflammatory response.

Indexed as

AnimalsCase-Control StudiesChemokine CCL20ChemokinesCluster AnalysisHepatitis, AlcoholicHepatitis C, ChronicHepatocytesHumansIntramolecular OxidoreductasesLipopolysaccharidesLiverMacrophage Migration-Inhibitory FactorsMiceMice, KnockoutNon-alcoholic Fatty Liver DiseaseChemokine CCL20ChemokinesIntramolecular OxidoreductasesLipopolysaccharidesMacrophage Migration-Inhibitory FactorsMIF protein, humanMif protein, mouseChemokinesHepatitisHepatologyInflammationInnate immunity

Identifiers

PMID33945507
PMCPMC8262327
OpenAlexW3159092249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.